12 Month Price Forecast For EWTX
Distance to EWTX Price Forecasts
EWTX Price Momentum
🤔 Considering Edgewise (EWTX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 22, 2025 7:35 PM UTC
EWTX Analyst Ratings & Price Targets
Based on our analysis of 9 Wall Street analysts, EWTX has a consensus that is bullish. The median price target is $45.00, with forecasts ranging from $42.00 to $51.00. Currently, there are 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With EWTX currently trading at $27.39, the median price forecast suggests a 64.3% upside. The most optimistic forecast comes from Yasmeen Rahimi at Piper Sandler, projecting a 86.2% upside, while Leonid Timashev at RBC Capital provides the most conservative target, suggesting a 53.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EWTX Analyst Consensus
EWTX Price Target Range
Latest EWTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EWTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 27, 2024 | Truist Securities | Srikripa Devarakonda | Buy | Maintains | $50.00 |
| Nov 22, 2024 | Evercore ISI Group | Cory Kasimov | Outperform | Initiates | $45.00 |
| Nov 8, 2024 | Wedbush | Laura Chico | Outperform | Maintains | $45.00 |
| Oct 11, 2024 | Piper Sandler | Yasmeen Rahimi | Overweight | Maintains | $51.00 |
| Sep 20, 2024 | RBC Capital | Leonid Timashev | Outperform | Maintains | $42.00 |
| Sep 19, 2024 | Truist Securities | Srikripa Devarakonda | Buy | Maintains | $33.00 |
| Sep 17, 2024 | RBC Capital | Leonid Timashev | Outperform | Maintains | $32.00 |
| Aug 16, 2024 | Wedbush | Laura Chico | Outperform | Reiterates | $31.00 |
| Aug 12, 2024 | JP Morgan | Tessa Romero | Overweight | Maintains | $31.00 |
| Jul 25, 2024 | RBC Capital | Leonid Timashev | Outperform | Reiterates | $32.00 |
| Jul 10, 2024 | RBC Capital | Leonid Timashev | Outperform | Reiterates | $32.00 |
| Jul 9, 2024 | JP Morgan | Tessa Romero | Overweight | Maintains | $30.00 |
| Jul 1, 2024 | Piper Sandler | Yasmeen Rahimi | Overweight | Maintains | $48.00 |
| Jun 26, 2024 | Wedbush | Laura Chico | Outperform | Reiterates | $31.00 |
| Apr 22, 2024 | RBC Capital | Leonid Timashev | Outperform | Maintains | $32.00 |
| Apr 17, 2024 | Truist Securities | Srikripa Devarakonda | Buy | Maintains | $25.00 |
| Apr 16, 2024 | Wedbush | Laura Chico | Outperform | Reiterates | $26.00 |
| Mar 12, 2024 | RBC Capital | Leonid Timashev | Outperform | Reiterates | $28.00 |
| Mar 7, 2024 | Piper Sandler | Yasmeen Rahimi | Overweight | Initiates | $48.00 |
| Nov 10, 2023 | Wedbush | Laura Chico | Outperform | Maintains | $23.00 |
Stocks Similar to Edgewise Therapeutics, Inc.
The following stocks are similar to Edgewise based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Edgewise Therapeutics, Inc. (EWTX) Financial Data
Edgewise Therapeutics, Inc. has a market capitalization of $3.09B with a P/E ratio of -17.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -31.9%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Edgewise Therapeutics, Inc. (EWTX) Company Overview
About Edgewise Therapeutics, Inc.
Develops therapies for muscle disorders.
The company focuses on discovering, developing, and commercializing biopharmaceutical therapies specifically targeting muscle disorders. It generates revenue through the development and potential commercialization of its product candidates, including its lead candidate EDG-5506, which is currently in Phase II trials for treating dystrophinopathies.
Founded in 2017 and based in Boulder, Colorado, Edgewise Therapeutics is advancing a pipeline of precision medicine products to address genetically defined muscle disorders, with an emphasis on innovative treatments for conditions like Duchenne muscular dystrophy and hypertrophic cardiomyopathy.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
108
CEO
Dr. Kevin Koch Ph.D.
Country
United States
IPO Year
2021
Website
www.edgewisetx.comEdgewise Therapeutics, Inc. (EWTX) Latest News & Analysis
Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development
12 hours agoEdgewise Therapeutics (Nasdaq: EWTX) announced executive changes to enhance leadership and focus on late-stage clinical development, appointing Dr. Robert Blaustein as Chief Development Officer.
Leadership changes at Edgewise Therapeutics signal a strategic shift towards late-stage clinical development, potentially enhancing the company's growth prospects and investor confidence.
Edgewise Therapeutics (Nasdaq: EWTX) reported progress in its drug pipeline and positive Phase 2 results, with upcoming priorities for 2025 presented at the J.P. Morgan Healthcare Conference.
Edgewise Therapeutics' positive Phase 2 results and strategic updates at a major healthcare conference signal potential growth and investment opportunities in the biopharmaceutical sector.
Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
15 days agoEdgewise Therapeutics, Inc. (Nasdaq: EWTX) will present at the J.P. Morgan Healthcare Conference on January 13, 2025, discussing updates on its cardiovascular and muscular dystrophy programs.
Edgewise Therapeutics' presentation at a major healthcare conference highlights potential advancements in key drug programs, influencing investor sentiment and stock performance based on future milestones.
The company reported positive phase 2 results for sevasemten in Becker Muscular Dystrophy, with key upcoming catalysts likely to enhance shareholder value and an expanding pipeline in related conditions.
Positive phase 2 results and upcoming regulatory meetings signal potential value increases. A diverse pipeline enhances growth prospects, making the company more attractive to investors.
Edgewise Therapeutics (EWTX) announced topline results from the Phase 2 CANYON trial of sevasemten for Becker muscular dystrophy (BMD), a genetic disorder causing muscle weakness.
Positive results from the Phase 2 trial for sevasemten could boost Edgewise's stock value and attract investment, indicating potential for successful treatment in a niche market.
Edgewise's experimental drug has shown promise in a mid-stage study by reducing levels of a biomarker associated with skeletal muscle damage.
The reduction of a biomarker linked to muscle damage suggests potential efficacy for Edgewise's drug, which could drive stock value and attract investor interest in future trials and approvals.
Frequently Asked Questions About EWTX Stock
What is Edgewise Therapeutics, Inc.'s (EWTX) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, Edgewise Therapeutics, Inc. (EWTX) has a median price target of $45.00. The highest price target is $51.00 and the lowest is $42.00.
Is EWTX stock a good investment in 2025?
According to current analyst ratings, EWTX has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $27.39. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for EWTX stock?
Wall Street analysts predict EWTX stock could reach $45.00 in the next 12 months. This represents a 64.3% increase from the current price of $27.39. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Edgewise Therapeutics, Inc.'s business model?
The company focuses on discovering, developing, and commercializing biopharmaceutical therapies specifically targeting muscle disorders. It generates revenue through the development and potential commercialization of its product candidates, including its lead candidate EDG-5506, which is currently in Phase II trials for treating dystrophinopathies.
What is the highest forecasted price for EWTX Edgewise Therapeutics, Inc.?
The highest price target for EWTX is $51.00 from Yasmeen Rahimi at Piper Sandler, which represents a 86.2% increase from the current price of $27.39.
What is the lowest forecasted price for EWTX Edgewise Therapeutics, Inc.?
The lowest price target for EWTX is $42.00 from Leonid Timashev at RBC Capital, which represents a 53.3% increase from the current price of $27.39.
What is the overall EWTX consensus from analysts for Edgewise Therapeutics, Inc.?
The overall analyst consensus for EWTX is bullish. Out of 9 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $45.00.
How accurate are EWTX stock price projections?
Stock price projections, including those for Edgewise Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
